An observational study in Hyperaldosteronism, Adrenal Venous Sampling and Adrenalectomy, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Recruiting at 76 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Observational
Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.
Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, yet its optimal diagnostic and therapeutic strategies remain challenging. Adrenal venous sampling (AVS) is regarded as the gold standard for subtype differentiation; however, important clinical, technical, and methodological issues have not been systematically addressed. This study is designed to comprehensively evaluate AVS and its clinical implications, aiming to elucidate the relationship between AVS-guided diagnosis and management of PA and long-term clinical and biochemical outcomes, while refining AVS protocols, standardizing clinical practice, optimizing therapeutic decision-making, and ultimately improving patient management and prognosis.
201 studies on the registry are indexed under Hyperaldosteronism; 93 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 200 across 103 observational studies indexed under Hyperaldosteronism.
Browse Hyperaldosteronism studies →Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 147 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients with confirmed primary aldosteronism underwent adrenal venous sampling.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
Procedure: adrenal venous sampling
Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
Major adverse cardiovascular events (MACE) at 1-year follow-up
Incidence of major adverse cardiovascular events (MACE) at 1-year follow-up, including stroke, heart failure, severe arrhythmias, renal failure, myocardial infarction, and death.
Time frame: 1 year after AVS procedure
The success rate of left adrenal venous sampling
Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava \>2 without ACTH simulation)
Time frame: At AVS procedure
The success rate of right adrenal venous sampling
Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava \>2 without ACTH simulation)
Time frame: At AVS procedure
The success rate of bilateral adrenal venous sampling
Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava \>2 without ACTH simulation)
Time frame: At AVS procedure
Selection of intraoperative catheter
Types of catheter at the time of Adrenal Venous Sampling via antecubital approach or femoral approach
Time frame: At AVS procedure
Time of the procedure
Time of the procedure
Time frame: At AVS procedure
Time of fluoroscopy
Time of fluoroscopy
Time frame: At AVS procedure
The contrast agent dosage
The contrast agent dosage
Time frame: At AVS procedure
the incidence of complications
Complications related to adrenal vein cannulations (adrenal vein hematoma, inferior vena cava dissection, puncture site hematoma, etc)
Time frame: 1 week after AVS procedure
the cost of the procedure
the cost of the procedure
Time frame: At AVS procedure
Change in 24-hour ambulatory systolic blood pressure
The difference in average systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) between baseline and each follow-up time point.
Time frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in 24-hour ambulatory diastolic blood pressure
The difference in average diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) bewteen baseline and each follow-up time point.
Time frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in office systolic blood pressure
The difference in systolic blood pressure measured during clinic visits (office blood pressure) between baseline and each follow-up time point
Time frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in office diastolic blood pressure
The difference in diastolic blood pressure measured during clinic visits (office blood pressure) between baseline and each follow-up time point
Time frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in antihypertensive medication burden
The change in the number and/or dosage of antihypertensive medications taken by patients between baseline and each follow-up time point
Time frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in urinary albumin-to-creatinine ratio (UACR)
The difference in urinary albumin-to-creatinine ratio measured at baseline and at each follow-up time point
Time frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in left ventricular mass index (LVMI)
The change in left ventricular mass index, as assessed by echocardiography, from baseline to each follow-up time point.
Time frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Change in pulse wave velocity (PWV) from baseline
The change in pulse wave velocity measured between baseline and each follow-up time point。
Time frame: At 1, 3, 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after treatment
Clinical Outcome According to Primary Aldosteronism Surgical Outcome (PASO) Criteria
Clinical outcomes will be assessed at each follow-up visit afteradrenal surgery according to the PASO consensus criteria. Outcomes will be categorized as: (1)Complete clinical success: normal blood pressure without the need for any antihypertensive medication. (2)Partial clinical success: improvement in blood pressure and/or a reduction in the number or dosage of antihypertensive medications. (3)Absent clinical success: no improvement in blood pressure or antihypertensive medication burden.
Time frame: At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery
Biochemical Outcome According to Primary Aldosteronism Surgical Outcome (PASO) Criteria
Biochemical outcomes will be assessed at each follow-up visit after adrenal surgery according to the PASO consensus classification. Outcomes will be categorized as:(1)Complete biochemical success: normal serum potassium levels and a normalized aldosterone-to-renin ratio (ARR) without the need for potassium supplementation.(2)Partial biochemical success: improvement in biochemical parameters without full normalization.(3)Absent biochemical success: no improvement in biochemical markers compared to baseline.
Time frame: At 6, 12, and 18 months; and 2, 3, 4, 5, and 10 years after surgery
Major adverse cardiovascular events (MACE)
Incidence of major adverse cardiovascular events (MACE), including stroke, heart failure, severe arrhythmias, renal failure, myocardial infarction, and death.
Time frame: At 6 and 18 months; and 2, 3, 4, 5, and 10 years after AVS procedure
Started Dec 2025 (actual). Primary completion is estimated for Aug 2029, 44 months after the start.
Of 64 non-industry observational studies under Hyperaldosteronism, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 96. This study's planned 44 months is below that.
Counting every sponsor, half of 64 studies reached it within 75 months; a quarter within 32 and three quarters within 96.
Start moved once since we started tracking on Sep 25, 2026: May 2025 → Dec 2025, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Academy of Medical Sciences, Fuwai Hospital →